# Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

> **NCT00126503** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 73 (actual)

## Conditions studied

- Chromophobe Renal Cell Carcinoma
- Clear Cell Renal Cell Carcinoma
- Papillary Renal Cell Carcinoma
- Recurrent Renal Cell Carcinoma
- Sarcomatoid Renal Cell Carcinoma
- Stage IV Renal Cell Cancer

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Sorafenib Tosylate
- **OTHER:** Pharmacological Study
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT00126503
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2011-10
- **Final completion:** 2012-02
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2015-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00126503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00126503, "Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00126503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*